Search research articles
Contact Us
Filters
Showing results (1-10 of 174) with videos related to
Page
of 18
Sort By:
Asia-Pacific Journal of Clinical Oncology
|
September 3, 2011
What constitutes a multidisciplinary team meeting?
Linda Mileshkin, John Zalcberg
Journal of Law and Medicine
|
February 11, 2012
Access to expensive anti-cancer drugs
Linda Mileshkin, Danny Sullivan
Leukemia & Lymphoma
|
November 17, 2006
The troublesome toxicity of peripheral neuropathy with thalidomide
Linda Mileshkin, H Miles Prince
Leukemia & Lymphoma
|
July 16, 2005
The adverse prognostic impact of advanced age in multiple myeloma
Linda Mileshkin, H Miles Prince
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 21, 2007
Longer consent forms for clinical trials compromise patient understanding: so why are they lengthening?
Emma Beardsley, Michael Jefford, Linda Mileshkin
The New England Journal of Medicine
|
February 17, 2012
Adjuvant trastuzumab in HER2-positive breast cancer
Ian Collins, Prudence Francis, Linda Mileshkin
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer
|
June 4, 2011
Patients' understanding of clinical trials needs to be assessed in the context of understanding of overall goals of care
Jaclyn Yoong, Michael Jefford, Linda Mileshkin
The New England Journal of Medicine
|
October 19, 2012
Early cardiovascular death in patients with cancer
Mark Voskoboynik, Damien Urban, Linda Mileshkin
Chemotherapy Research and Practice
|
June 6, 2012
Predictive Molecular Tumour Testing: What Are the Obstacles between Bench and Bedside?
Linda Mileshkin, Bhaumik Shah, Michael Michael
Drugs & Aging
|
September 28, 2007
Treatment strategies in elderly patients with multiple myeloma: current status
Hang Quach, H Miles Prince, Linda Mileshkin
Page
of 18
Search research articles
Search
Showing results (1-10 of 174) with videos related to
Sort By:
Page
of 18
Asia-Pacific Journal of Clinical Oncology
|
September 3, 2011
What constitutes a multidisciplinary team meeting?
Linda Mileshkin, John Zalcberg
Journal of Law and Medicine
|
February 11, 2012
Access to expensive anti-cancer drugs
Linda Mileshkin, Danny Sullivan
Leukemia & Lymphoma
|
November 17, 2006
The troublesome toxicity of peripheral neuropathy with thalidomide
Linda Mileshkin, H Miles Prince
Leukemia & Lymphoma
|
July 16, 2005
The adverse prognostic impact of advanced age in multiple myeloma
Linda Mileshkin, H Miles Prince
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 21, 2007
Longer consent forms for clinical trials compromise patient understanding: so why are they lengthening?
Emma Beardsley, Michael Jefford, Linda Mileshkin
The New England Journal of Medicine
|
February 17, 2012
Adjuvant trastuzumab in HER2-positive breast cancer
Ian Collins, Prudence Francis, Linda Mileshkin
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer
|
June 4, 2011
Patients' understanding of clinical trials needs to be assessed in the context of understanding of overall goals of care
Jaclyn Yoong, Michael Jefford, Linda Mileshkin
The New England Journal of Medicine
|
October 19, 2012
Early cardiovascular death in patients with cancer
Mark Voskoboynik, Damien Urban, Linda Mileshkin
Chemotherapy Research and Practice
|
June 6, 2012
Predictive Molecular Tumour Testing: What Are the Obstacles between Bench and Bedside?
Linda Mileshkin, Bhaumik Shah, Michael Michael
Drugs & Aging
|
September 28, 2007
Treatment strategies in elderly patients with multiple myeloma: current status
Hang Quach, H Miles Prince, Linda Mileshkin
Page
of 18